You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMirabegron
Accession NumberDB08893
TypeSmall Molecule
GroupsApproved
DescriptionMirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012.
Structure
Thumb
Synonyms
Myrbetriq
External Identifiers
  • YM-178
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet25 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaProlonged-release tablet50 mgOral useAstellas Pharma Europe B.V.2012-12-20Not applicableEu
Myrbetriqtablet, film coated, extended release25 mg/1oralAstellas Pharma US, Inc.2012-06-28Not applicableUs
Myrbetriqtablet, film coated, extended release25 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Myrbetriqtablet, film coated, extended release50 mg/1oralAstellas Pharma US, Inc.2012-06-28Not applicableUs
Myrbetriqtablet (extended-release)25 mgoralAstellas Pharma Canada Inc2013-03-28Not applicableCanada
Myrbetriqtablet (extended-release)50 mgoralAstellas Pharma Canada Inc2013-03-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetanisNot Available
Metmiga Not Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIMVR3JL3B2V
CAS number223673-61-8
WeightAverage: 396.506
Monoisotopic: 396.161996722
Chemical FormulaC21H24N4O2S
InChI KeyInChIKey=PBAPPPCECJKMCM-IBGZPJMESA-N
InChI
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
IUPAC Name
2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
SMILES
NC1=NC(CC(=O)NC2=CC=C(CCNC[[email protected]](O)C3=CC=CC=C3)C=C2)=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylamides. These are organic compounds that contain a carboxamide group that is N-linked to a aryl group. They have the generic structure RC(=O)N(R')H, R = organyl group and R'= aryl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassN-arylamides
Sub ClassNot Available
Direct ParentN-arylamides
Alternative Parents
Substituents
  • N-arylamide
  • Phenethylamine
  • Aralkylamine
  • 2,4-disubstituted 1,3-thiazole
  • Benzenoid
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary amine
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationMirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
PharmacodynamicsMirabegron has little effect on the mean maximum flow rate or mean detrusor pressure at maximum flow rate in patients with lower urinary tract symptoms and bladder outlet obstruction. Furthermore, mirabegron increases blood pressure in a dose dependent manner. However, this effect is reversible when mirabegron is discontinued. Mirabegron also increases heart rate in a dose dependent manner. The dose in which half-maximal efficacy is demonstrated is 25 mg. Comparatively, the dose in which maximal efficacy is demonstrated is 100 mg.
Mechanism of actionMirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Once beta-3 receptors are activated, the detrusor smooth muscle relaxes to allow for a larger bladder capacity. At higher doses (200 mg), there is a potential for mirabegron to activate beta-1 and beta-2 adrenergic receptors.
Related Articles
AbsorptionThe absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose. Tmax, oral dose, healthy subjects= 3.5 hours;
Volume of distribution

Vd, steady state, IV dose = 1670 L. This high value suggests that mirabegron is extensively distributed in the body.

Protein binding71% bound to plasma proteins. It binds to albumin and alpha-1-acid glycoprotein with moderate affinity.
Metabolism

Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. The major circulating entity is mirabegron. Two major and inactive metabolites (phase 2 glucuronides) are produced. Although mirabegron is a substrate for CYP2D6 and CYP3A4, its role in the elimination of the drug is limited. Studies also suggest that CYP3A4 is the main enzyme that facilitates the oxidative metabolism of the drug. Furthermore, butylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT), and possibly alcohol dehydrogenase may be involved with the metabolism of mirabegron.

Route of eliminationMirabegron is eliminated via urine (radiolabeled drug: 55%; unchanged drug: ~25%) and feces (radiolabeled drug: 34%; unchanged drug: 0%). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Extent of elimination via urine is dose-dependent.
Half lifeTerminal elimination half-life = 50 hours
Clearance

Total body clearance (CLtot), IV dose = 57 L/h;
Renal clearance (CLR) = 13 L/h

ToxicityMost commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9398
Blood Brain Barrier+0.8115
Caco-2 permeable-0.6462
P-glycoprotein substrateSubstrate0.5567
P-glycoprotein inhibitor INon-inhibitor0.8492
P-glycoprotein inhibitor IINon-inhibitor0.8487
Renal organic cation transporterNon-inhibitor0.7223
CYP450 2C9 substrateNon-substrate0.7656
CYP450 2D6 substrateNon-substrate0.7786
CYP450 3A4 substrateNon-substrate0.641
CYP450 1A2 substrateNon-inhibitor0.5904
CYP450 2C9 inhibitorInhibitor0.6156
CYP450 2D6 inhibitorNon-inhibitor0.8873
CYP450 2C19 inhibitorNon-inhibitor0.574
CYP450 3A4 inhibitorInhibitor0.5223
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5711
Ames testNon AMES toxic0.6422
CarcinogenicityNon-carcinogens0.8972
BiodegradationNot ready biodegradable0.5977
Rat acute toxicity2.4527 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9094
hERG inhibition (predictor II)Inhibitor0.567
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Prolonged-release tabletOral use25 mg
Prolonged-release tabletOral use50 mg
Tablet (extended-release)oral25 mg
Tablet (extended-release)oral50 mg
Tablet, film coated, extended releaseoral25 mg/1
Tablet, film coated, extended releaseoral50 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2305802 No2008-11-182018-10-15Canada
CA2464068 No2007-10-162022-10-29Canada
CA2503570 No2023-11-042011-04-19Canada
US6346532 No1998-10-152018-10-15Us
US6562375 No2000-08-012020-08-01Us
US7342117 No2003-11-042023-11-04Us
US7750029 No2003-12-182023-12-18Us
US7982049 No2003-11-042023-11-04Us
US8835474 No2003-11-042023-11-04Us
USRE44872 No2003-12-182023-12-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00412 mg/mLALOGPS
logP2.2ALOGPS
logP2.89ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area100.27 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity113.23 m3·mol-1ChemAxon
Polarizability44.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899 ]
External Links
ATC CodesG04BD12
AHFS Codes
  • 86:12
PDB EntriesNot Available
FDA labelDownload (510 KB)
MSDSDownload (481 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Mirabegron.
AbirateroneThe metabolism of Mirabegron can be decreased when combined with Abiraterone.
AcetaminophenThe serum concentration of Mirabegron can be increased when it is combined with Acetaminophen.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Mirabegron.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Mirabegron.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.
AfatinibThe serum concentration of Mirabegron can be increased when it is combined with Afatinib.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Mirabegron.
AlbendazoleThe serum concentration of Mirabegron can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Mirabegron can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Mirabegron can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Mirabegron can be increased when it is combined with Alfentanil.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Mirabegron.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Mirabegron.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Mirabegron.
AmantadineThe serum concentration of Mirabegron can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Mirabegron can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Mirabegron.
AmiodaroneThe serum concentration of Mirabegron can be decreased when it is combined with Amiodarone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Mirabegron.
AmitriptylineThe serum concentration of Mirabegron can be increased when it is combined with Amitriptyline.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Mirabegron.
AmlodipineThe serum concentration of Mirabegron can be increased when it is combined with Amlodipine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Mirabegron.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Mirabegron.
AmprenavirThe serum concentration of Mirabegron can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Mirabegron.
AmsacrineThe serum concentration of Mirabegron can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Mirabegron.
AnagrelideMirabegron may increase the QTc-prolonging activities of Anagrelide.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mirabegron.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Mirabegron.
AprepitantThe serum concentration of Mirabegron can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Mirabegron.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Mirabegron.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.
Arsenic trioxideMirabegron may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe metabolism of Mirabegron can be decreased when combined with Artemether.
AsenapineMirabegron may increase the QTc-prolonging activities of Asenapine.
AstemizoleThe serum concentration of Mirabegron can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Mirabegron.
AtazanavirThe serum concentration of Mirabegron can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Mirabegron can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Mirabegron can be increased when it is combined with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mirabegron.
AzelastineThe serum concentration of Mirabegron can be increased when it is combined with Azelastine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Mirabegron.
AzithromycinMirabegron may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Mirabegron can be increased when it is combined with Azithromycin.
BedaquilineMirabegron may increase the QTc-prolonging activities of Bedaquiline.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Mirabegron.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mirabegron.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Mirabegron.
BenzocaineThe serum concentration of Mirabegron can be increased when it is combined with Benzocaine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Mirabegron.
BepridilThe serum concentration of Mirabegron can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Mirabegron.
BetaxololThe metabolism of Mirabegron can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Mirabegron can be decreased when it is combined with Bexarotene.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Mirabegron.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.
BoceprevirThe metabolism of Mirabegron can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Mirabegron can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mirabegron can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Mirabegron can be increased when it is combined with Bosutinib.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mirabegron.
BromocriptineThe serum concentration of Mirabegron can be increased when it is combined with Bromocriptine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Mirabegron.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Mirabegron.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Mirabegron.
BuprenorphineThe serum concentration of Mirabegron can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Mirabegron.
BupropionThe metabolism of Bupropion can be decreased when combined with Mirabegron.
BuspironeThe serum concentration of Mirabegron can be increased when it is combined with Buspirone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Mirabegron.
CabazitaxelThe serum concentration of Mirabegron can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Mirabegron can be increased when it is combined with Caffeine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Mirabegron.
CanagliflozinThe serum concentration of Mirabegron can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Mirabegron can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Mirabegron can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Mirabegron.
CarbamazepineThe serum concentration of Mirabegron can be decreased when it is combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Mirabegron.
CarteololThe metabolism of Carteolol can be decreased when combined with Mirabegron.
CarvedilolThe serum concentration of Mirabegron can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Mirabegron.
CaspofunginThe serum concentration of Mirabegron can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Mirabegron can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Mirabegron.
CeritinibThe serum concentration of Mirabegron can be increased when it is combined with Ceritinib.
CeritinibMirabegron may increase the QTc-prolonging activities of Ceritinib.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Mirabegron.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Mirabegron.
ChloroquineMirabegron may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Mirabegron can be increased when it is combined with Chloroquine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Mirabegron.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Mirabegron.
ChlorpromazineMirabegron may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Mirabegron can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Mirabegron can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Mirabegron can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Mirabegron.
CholecalciferolThe metabolism of Mirabegron can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Mirabegron can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Mirabegron can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Mirabegron can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Mirabegron.
CimetidineThe serum concentration of Mirabegron can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Mirabegron can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Mirabegron.
CiprofloxacinMirabegron may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Mirabegron can be increased when it is combined with Ciprofloxacin.
CisaprideMirabegron may increase the QTc-prolonging activities of Cisapride.
CitalopramThe serum concentration of Mirabegron can be increased when it is combined with Citalopram.
CitalopramThe metabolism of Citalopram can be decreased when combined with Mirabegron.
ClarithromycinMirabegron may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Mirabegron can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Mirabegron can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Mirabegron.
ClobazamThe metabolism of Mirabegron can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Mirabegron can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Mirabegron can be increased when it is combined with Clomipramine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Mirabegron.
ClonidineThe metabolism of Clonidine can be decreased when combined with Mirabegron.
ClotrimazoleThe metabolism of Mirabegron can be decreased when combined with Clotrimazole.
ClozapineMirabegron may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Mirabegron can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Mirabegron can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Mirabegron can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Mirabegron.
ColchicineThe serum concentration of Mirabegron can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Mirabegron can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Mirabegron can be increased when it is combined with Conivaptan.
CrizotinibMirabegron may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Mirabegron can be decreased when combined with Crizotinib.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mirabegron.
CyclophosphamideThe serum concentration of Mirabegron can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Mirabegron.
CyclosporineThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Mirabegron can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Mirabegron can be increased when it is combined with Dactinomycin.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Mirabegron.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Mirabegron.
DarunavirThe serum concentration of Mirabegron can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Mirabegron.
DasatinibThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Mirabegron can be decreased when it is combined with Daunorubicin.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Mirabegron.
DeferasiroxThe serum concentration of Mirabegron can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mirabegron can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.
DexamethasoneThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mirabegron.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Mirabegron.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Mirabegron.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Mirabegron.
DextromethorphanThe serum concentration of Mirabegron can be increased when it is combined with Dextromethorphan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Mirabegron.
DiclofenacThe serum concentration of Mirabegron can be increased when it is combined with Diclofenac.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mirabegron.
DigoxinThe serum concentration of Mirabegron can be decreased when it is combined with Digoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.
DihydroergotamineThe metabolism of Mirabegron can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Mirabegron can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Mirabegron can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Mirabegron can be increased when it is combined with Dipyridamole.
DisopyramideMirabegron may increase the QTc-prolonging activities of Disopyramide.
DofetilideMirabegron may increase the QTc-prolonging activities of Dofetilide.
DolasetronMirabegron may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Mirabegron.
DonepezilThe metabolism of Donepezil can be decreased when combined with Mirabegron.
DopamineThe metabolism of Dopamine can be decreased when combined with Mirabegron.
DoxazosinThe serum concentration of Mirabegron can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Mirabegron.
DoxepinThe serum concentration of Mirabegron can be increased when it is combined with Doxepin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Mirabegron.
DoxorubicinThe serum concentration of Mirabegron can be decreased when it is combined with Doxorubicin.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Mirabegron.
DoxycyclineThe metabolism of Mirabegron can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Mirabegron can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Mirabegron can be decreased when combined with Dronedarone.
DroperidolMirabegron may increase the QTc-prolonging activities of Droperidol.
DuloxetineThe metabolism of Mirabegron can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Mirabegron can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Mirabegron can be increased when it is combined with Elbasvir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Mirabegron.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Mirabegron.
EnalaprilThe serum concentration of Mirabegron can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Mirabegron.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Mirabegron.
EnzalutamideThe serum concentration of Mirabegron can be increased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Mirabegron.
ErgonovineThe serum concentration of Mirabegron can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Mirabegron can be increased when it is combined with Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Mirabegron.
ErythromycinMirabegron may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Mirabegron can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Mirabegron.
Eslicarbazepine acetateThe serum concentration of Mirabegron can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Mirabegron.
EstramustineThe serum concentration of Mirabegron can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Mirabegron can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Mirabegron can be decreased when it is combined with Estrone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mirabegron.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Mirabegron.
EtoposideThe serum concentration of Mirabegron can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.
EtravirineThe serum concentration of Mirabegron can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of Mirabegron can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Mirabegron can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Mirabegron.
FexofenadineThe serum concentration of Mirabegron can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Mirabegron can be increased when it is combined with Fidaxomicin.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Mirabegron.
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Mirabegron.
FluconazoleThe metabolism of Mirabegron can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Mirabegron.
FluoxetineThe serum concentration of Mirabegron can be increased when it is combined with Fluoxetine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Mirabegron.
FlupentixolThe serum concentration of Mirabegron can be increased when it is combined with Flupentixol.
FlupentixolMirabegron may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Mirabegron can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Mirabegron.
FlurazepamThe serum concentration of Mirabegron can be increased when it is combined with Flurazepam.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Mirabegron.
FluvoxamineThe metabolism of Mirabegron can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Mirabegron.
FosamprenavirThe metabolism of Mirabegron can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mirabegron can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Mirabegron can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Mirabegron can be increased when it is combined with Fusidic Acid.
Gadobenic acidMirabegron may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Mirabegron.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mirabegron.
GefitinibThe serum concentration of Mirabegron can be increased when it is combined with Gefitinib.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Mirabegron.
GemifloxacinMirabegron may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Mirabegron can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Mirabegron can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Mirabegron can be increased when it is combined with Glycerol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Mirabegron.
GoserelinMirabegron may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Mirabegron can be increased when it is combined with Gramicidin D.
GranisetronMirabegron may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe serum concentration of Mirabegron can be increased when it is combined with Grepafloxacin.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Mirabegron.
HaloperidolMirabegron may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Mirabegron can be increased when it is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Mirabegron.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Mirabegron.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.
HydrocortisoneThe serum concentration of Mirabegron can be increased when it is combined with Hydrocortisone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Mirabegron.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mirabegron.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Mirabegron.
IbutilideMirabegron may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Mirabegron.
IdelalisibThe serum concentration of Mirabegron can be increased when it is combined with Idelalisib.
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Mirabegron.
ImatinibThe metabolism of Mirabegron can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Mirabegron can be increased when it is combined with Imipramine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Mirabegron.
IndinavirThe serum concentration of Mirabegron can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Mirabegron can be increased when it is combined with Indomethacin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Mirabegron.
IsavuconazoniumThe metabolism of Mirabegron can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Mirabegron can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Mirabegron can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Mirabegron can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Mirabegron can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Mirabegron can be increased when it is combined with Ivermectin.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Mirabegron.
KetamineThe serum concentration of Mirabegron can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Mirabegron can be increased when it is combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Mirabegron.
LansoprazoleThe serum concentration of Mirabegron can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Mirabegron can be increased when it is combined with Lapatinib.
LenvatinibMirabegron may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideMirabegron may increase the QTc-prolonging activities of Leuprolide.
LevodopaThe metabolism of Levodopa can be decreased when combined with Mirabegron.
LevofloxacinMirabegron may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Mirabegron can be increased when it is combined with Levofloxacin.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Mirabegron.
LevothyroxineThe serum concentration of Mirabegron can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Mirabegron can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Mirabegron.
LiothyronineThe serum concentration of Mirabegron can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Mirabegron can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Mirabegron can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Mirabegron.
LomitapideThe serum concentration of Mirabegron can be increased when it is combined with Lomitapide.
LomustineThe metabolism of Lomustine can be decreased when combined with Mirabegron.
LoperamideThe serum concentration of Mirabegron can be increased when it is combined with Loperamide.
LoperamideThe metabolism of Loperamide can be decreased when combined with Mirabegron.
LopinavirThe serum concentration of Mirabegron can be increased when it is combined with Lopinavir.
LopinavirMirabegron may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Mirabegron can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Mirabegron.
LorcaserinThe metabolism of Mirabegron can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Mirabegron can be increased when it is combined with Losartan.
LovastatinThe metabolism of Mirabegron can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Mirabegron can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Mirabegron can be decreased when it is combined with Lumacaftor.
LumefantrineMirabegron may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Mirabegron can be decreased when combined with Lumefantrine.
MaprotilineThe serum concentration of Mirabegron can be increased when it is combined with Maprotiline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Mirabegron.
MebendazoleThe serum concentration of Mirabegron can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.
MefloquineThe serum concentration of Mirabegron can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Mirabegron can be increased when it is combined with Megestrol acetate.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Mirabegron.
MeprobamateThe serum concentration of Mirabegron can be increased when it is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Mirabegron.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.
MethadoneMirabegron may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Mirabegron can be increased when it is combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Mirabegron.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Mirabegron.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Mirabegron.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Mirabegron.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Mirabegron.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Mirabegron.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Mirabegron.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Mirabegron.
MetoprololMirabegron may decrease the antihypertensive activities of Metoprolol.
MetoprololThe serum concentration of Mirabegron can be increased when it is combined with Metoprolol.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Mirabegron.
MianserinThe metabolism of Mianserin can be decreased when combined with Mirabegron.
MibefradilThe serum concentration of Mirabegron can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Mirabegron can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Mirabegron can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Mirabegron can be decreased when combined with Mifepristone.
MifepristoneMirabegron may increase the QTc-prolonging activities of Mifepristone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Mirabegron.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Mirabegron can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Mirabegron can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mirabegron can be decreased when it is combined with Mitoxantrone.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Mirabegron.
ModafinilThe serum concentration of Mirabegron can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Mirabegron can be increased when it is combined with Morphine.
MorphineThe metabolism of Morphine can be decreased when combined with Mirabegron.
MoxifloxacinMirabegron may increase the QTc-prolonging activities of Moxifloxacin.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Mirabegron.
NafcillinThe serum concentration of Mirabegron can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Mirabegron can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Mirabegron can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Mirabegron.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.
NefazodoneThe serum concentration of Mirabegron can be decreased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Mirabegron.
NelfinavirThe serum concentration of Mirabegron can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Mirabegron can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Mirabegron can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Mirabegron.
NevirapineThe metabolism of Mirabegron can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Mirabegron can be increased when it is combined with Nicardipine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Mirabegron.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Mirabegron.
NicotineThe metabolism of Nicotine can be decreased when combined with Mirabegron.
NifedipineThe serum concentration of Mirabegron can be decreased when it is combined with Nifedipine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Mirabegron.
NilotinibThe metabolism of Mirabegron can be decreased when combined with Nilotinib.
NilotinibMirabegron may increase the QTc-prolonging activities of Nilotinib.
NisoldipineThe serum concentration of Mirabegron can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Mirabegron can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Mirabegron can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Mirabegron.
NorethisteroneThe serum concentration of Mirabegron can be decreased when it is combined with Norethisterone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Mirabegron.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Mirabegron.
OfloxacinMirabegron may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Mirabegron.
OlaparibThe metabolism of Mirabegron can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Mirabegron can be increased when it is combined with Omeprazole.
OndansetronMirabegron may increase the QTc-prolonging activities of Ondansetron.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mirabegron.
OsimertinibThe serum concentration of Mirabegron can be increased when it is combined with Osimertinib.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Mirabegron.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Mirabegron.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mirabegron.
P-NitrophenolThe serum concentration of Mirabegron can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Mirabegron can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.
PaliperidoneMirabegron may increase the QTc-prolonging activities of Paliperidone.
Palmitic AcidThe serum concentration of Mirabegron can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Mirabegron.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.
PanobinostatMirabegron may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Mirabegron can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Mirabegron can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Mirabegron can be increased when it is combined with Paroxetine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Mirabegron.
PazopanibMirabegron may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineMirabegron may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Mirabegron can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Mirabegron.
PerflutrenMirabegron may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Mirabegron.
PerindoprilThe serum concentration of Mirabegron can be increased when it is combined with Perindopril.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Mirabegron.
PethidineThe metabolism of Pethidine can be decreased when combined with Mirabegron.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Mirabegron.
PhenforminThe metabolism of Phenformin can be decreased when combined with Mirabegron.
PhenobarbitalThe serum concentration of Mirabegron can be decreased when it is combined with Phenobarbital.
PhenytoinThe metabolism of Mirabegron can be increased when combined with Phenytoin.
PimozideThe serum concentration of Mirabegron can be increased when it is combined with Pimozide.
PimozideMirabegron may increase the QTc-prolonging activities of Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Mirabegron.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.
PiperazineThe metabolism of Piperazine can be decreased when combined with Mirabegron.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Mirabegron.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.
Platelet Activating FactorThe serum concentration of Mirabegron can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Mirabegron can be increased when it is combined with Ponatinib.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Mirabegron.
PosaconazoleThe serum concentration of Mirabegron can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Mirabegron can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Mirabegron can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Mirabegron can be increased when it is combined with Prednisone.
PrimaquineMirabegron may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Mirabegron can be increased when combined with Primidone.
ProbenecidThe serum concentration of Mirabegron can be increased when it is combined with Probenecid.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Mirabegron.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Mirabegron.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mirabegron.
ProgesteroneThe serum concentration of Mirabegron can be decreased when it is combined with Progesterone.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Mirabegron.
PromazineMirabegron may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Mirabegron can be decreased when combined with Promazine.
PromethazineThe serum concentration of Mirabegron can be increased when it is combined with Promethazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Mirabegron.
PropafenoneThe serum concentration of Mirabegron can be increased when it is combined with Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Mirabegron.
PropofolThe metabolism of Propofol can be decreased when combined with Mirabegron.
PropranololThe serum concentration of Mirabegron can be increased when it is combined with Propranolol.
PropranololThe metabolism of Propranolol can be decreased when combined with Mirabegron.
ProtriptylineThe serum concentration of Mirabegron can be increased when it is combined with Protriptyline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Mirabegron.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Mirabegron.
QuercetinThe serum concentration of Mirabegron can be increased when it is combined with Quercetin.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Mirabegron.
QuinacrineThe serum concentration of Mirabegron can be increased when it is combined with Quinacrine.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mirabegron.
QuinidineMirabegron may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Mirabegron can be increased when it is combined with Quinine.
QuinineThe metabolism of Quinine can be decreased when combined with Mirabegron.
RanitidineThe serum concentration of Mirabegron can be increased when it is combined with Ranitidine.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Mirabegron.
RanolazineThe serum concentration of Mirabegron can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Mirabegron can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Mirabegron can be increased when it is combined with Regorafenib.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Mirabegron.
repinotanThe metabolism of repinotan can be decreased when combined with Mirabegron.
ReserpineThe serum concentration of Mirabegron can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Mirabegron can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Mirabegron can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Mirabegron can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Mirabegron can be increased when it is combined with Rilpivirine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Mirabegron.
RitonavirThe serum concentration of Mirabegron can be decreased when it is combined with Ritonavir.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Mirabegron.
RolapitantThe serum concentration of Mirabegron can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Mirabegron can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Mirabegron.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Mirabegron.
SaquinavirMirabegron may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Mirabegron can be decreased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mirabegron.
SelegilineThe serum concentration of Mirabegron can be increased when it is combined with Selegiline.
SertindoleThe metabolism of Sertindole can be decreased when combined with Mirabegron.
SertralineThe serum concentration of Mirabegron can be increased when it is combined with Sertraline.
SertralineThe metabolism of Sertraline can be decreased when combined with Mirabegron.
SildenafilThe metabolism of Mirabegron can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Mirabegron can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mirabegron can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Mirabegron can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Mirabegron.
SirolimusThe serum concentration of Mirabegron can be decreased when it is combined with Sirolimus.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Mirabegron.
SorafenibThe serum concentration of Mirabegron can be increased when it is combined with Sorafenib.
SotalolMirabegron may increase the QTc-prolonging activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Mirabegron.
SpironolactoneThe serum concentration of Mirabegron can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Mirabegron can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Mirabegron can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Mirabegron can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Mirabegron can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Mirabegron can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleMirabegron may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Mirabegron can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Mirabegron can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Mirabegron can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Mirabegron can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Mirabegron can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Mirabegron can be decreased when it is combined with Tamoxifen.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Mirabegron.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Mirabegron.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Mirabegron.
Taurocholic AcidThe serum concentration of Mirabegron can be increased when it is combined with Taurocholic Acid.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Mirabegron.
TelaprevirThe metabolism of Mirabegron can be decreased when combined with Telaprevir.
TelavancinMirabegron may increase the QTc-prolonging activities of Telavancin.
TelithromycinMirabegron may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Mirabegron can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Mirabegron can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Mirabegron can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Mirabegron can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Mirabegron can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Mirabegron can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Mirabegron.
TesmilifeneThe serum concentration of Mirabegron can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Mirabegron.
TestosteroneThe serum concentration of Mirabegron can be increased when it is combined with Testosterone.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Mirabegron.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Mirabegron.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.
ThioridazineThe metabolism of Mirabegron can be decreased when combined with Thioridazine.
TicagrelorThe serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Mirabegron can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Mirabegron.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Mirabegron.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Mirabegron.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Mirabegron.
TocilizumabThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Mirabegron.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Mirabegron.
TolvaptanThe serum concentration of Mirabegron can be increased when it is combined with Tolvaptan.
ToremifeneMirabegron may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Mirabegron.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.
TranylcypromineThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.
TrazodoneThe serum concentration of Mirabegron can be decreased when it is combined with Trazodone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Mirabegron.
TrifluoperazineThe serum concentration of Mirabegron can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Mirabegron can be increased when it is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mirabegron.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Mirabegron.
TrimethoprimThe serum concentration of Mirabegron can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Mirabegron can be increased when it is combined with Trimipramine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Mirabegron.
TroleandomycinThe serum concentration of Mirabegron can be increased when it is combined with Troleandomycin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mirabegron.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mirabegron.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mirabegron.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Mirabegron.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Mirabegron.
VandetanibMirabegron may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.
VemurafenibMirabegron may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Mirabegron can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Mirabegron can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Mirabegron.
VinblastineThe serum concentration of Mirabegron can be decreased when it is combined with Vinblastine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Mirabegron.
VincristineThe serum concentration of Mirabegron can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Mirabegron can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Mirabegron.
VoriconazoleThe metabolism of Mirabegron can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Mirabegron.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Mirabegron.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Mirabegron.
ZimelidineThe serum concentration of Mirabegron can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Mirabegron can be decreased when combined with Ziprasidone.
ZiprasidoneMirabegron may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Mirabegron.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Mirabegron.
Food Interactions
  • When taken with meals, levels of mirabegron decreased. Furthermore, the magnitude of this effect was greater if taken with a low fat meal, rather than a high fat meal. Despite these findings, dose adjustment is not required.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188 ]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188 ]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393 ]
Comments
comments powered by Disqus
Drug created on May 30, 2013 23:44 / Updated on September 24, 2016 02:17